Eribulin (Halaven): A new, effective treatment for women with heavily pretreated metastatic breast cancer

Breast Cancer: Targets and Therapy

Volumn 3, Issue , 2011, Pages 101-111

  Menis, J ^a   Twelves, C ^b  

^a SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Eribulin; Metastatic breast cancer; Pretreated

Indexed keywords

EID: 84856404932     PISSN: None     EISSN: 11791314     Source Type: Journal    
DOI: 10.2147/BCTT.S21741     Document Type: Review

References (56)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin. 2010;60:277-300.
2. Parkin DM, Fernández LM. Use of statistics to assess the global burden of breast cancer. Breast J. 2006;12(Suppl 1):S70-S80.
3. Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN. Is breast cancer survival improving? Cancer. 2004;100:44-52.
4. Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28:3271-3277.
5. Gianni L, Norton L, Wolmark N, Suter TM, Bonadonna G, Hortobagyi GN. Role of anthracyclines in the treatment of early breast cancer. J Clin Oncol. 2009;27:4798-4808.
6. Martín M, Seguí MA, Antón A, et al. Adjuvant docetaxel for high-risk, node-negative breast cancer. N Engl J Med. 2010;363: 2200-2210.
7. Loesch D, Greco FA, Senzer NN, et al. Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for women with high-risk breast cancer. J Clin Oncol. 2010;28:2958-2965.
8. Bedard PL, Di Leo A, Piccart-Gebhart MJ. Taxanes: Optimizing adjuvant chemotherapy for early-stage breast cancer. Nat Rev Clin Oncol. 2010;7:22-36.
9. O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005;10(Suppl 3):20-29.
10. Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a Phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2007;25:3407-3414.
11. Seo HY, Lee HJ, Woo OH, et al. Phase II study of vinorelbine monotherapy in anthracycline and taxane pre-treated metastatic breast cancer. Invest New Drugs. 2011;29:360-365.
12. Spielmann M, Llombart-Cussac A, Kalla S, et al. Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology. 2001;60:303-307.
13. Robert NJ, Conkling PR, O'Rourke MA, et al. Results of a Phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer. Breast Cancer Res Treat. 2011;126:101-108.
14. Chew HK, Doroshow JH, Frankel P, et al. Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer. J Clin Oncol. 2009;27:2163-2169.
15. Murphy CG, Seidman AD. Evolving approaches to metastatic breast cancer previously treated with anthracyclines and taxanes. Clin Breast Cancer. 2009;9:S58-S65.
16. Newman DJ, Cragg GM, Battershill CN. Therapeutic agents from the sea: Biodiversity, chemo-evolutionary insight and advances to the end of Darwin's 200th year. Diving Hyperb Med. 2009;39:216-225.
17. Hirata Y, Uemura D. Halichondrins: Antitumor polyether macrolides from a marine sponge. Pure Appl Chem. 1986;58:701-710.
18. Towle MJ, Salvato KA, Budrow J, et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 2001;61:1013-1021.
19. Pettit GR, Herald CL, Boyd MR, et al. Isolation and structure of the cell growth inhibitory constituents from the western Pacific marine sponge Axinella sp. J Med Chem. 1991;34:3339-3340.
20. Aicher TD, Buszek KR, Fang FG, et al. Total synthesis of halichondrin B and Norhalichondrin B. J Am Chem Soc. 1992;114:3162-3164.
21. Stamos DP, Chen SS, Kishi Y. New synthetic route to the C.14- C.38 segment of halichondrins. J Org Chem. 1997;62:7552-7553.
22. Wang Y, Habgood GJ, Christ WJ, Kishi Y, Littlefield BA, Melvin JY. Structure-activity relationships of halichondrin B analogues: Modifications at C.30M//C.38. Bioorg Med Chem Lett. 2000;10: 1029-1032.
23. Bai RL, Paull KD, Herald CL, Malspeis L, Pettit GR, Hamel E. Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J Biol Chem. 1991;266:15882-15889.
24. Jordan MA, Kamath K, Manna T, et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther. 2005;4:1086-1095.
25. Dabydeen DA, Burnett JC, Bai R, et al. Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin. Mol Pharmacol. 2006;70:1866-1875.
26. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4:253-265.
27. Alday PH, Correia JJ. Macromolecular interaction of halichondrin B analogues eribulin (E7389) and ER-076349 with tubulin by analytical ultracentrifugation. Biochemistry. 2009;48:7927-7938.
28. Okouneva T, Azarenko O, Wilson L, Littlefield BA, Jordan MA. Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther. 2008;7:2003-2011.
29. Kuznetsov G, Towle MJ, Cheng H, et al. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res. 2004; 64:5760-5766.
30. Kuznetsov G, TenDyke K, Yu MJ, Littlefield BA, Yu J, Littlefield BA. Antiproliferative effects of halichondrin B analog eribulin mesylate (E7389) against paclitaxel-resistant human cancer cells in vitro. Proceedings of the annual meeting of American Association for Cancer Research, Los Angeles, CA, April 14-18, 2007. Abstr C58.
31. Agoulnik S, Kuznetsov G, Tendyke K, et al. Sensitivity to halichondrin analog E7389 and hemiasterlin analog E7974 correlates with aIII tubulin istotype expression in human breast cancer cell lines. J Clin Oncol. 2005;23(16 Suppl):2012.
32. Alley MC, Smith AC, Donohue SJ, et al. Comparison of the relative efficacies and toxicities of halichondrin B analogues. Proceedings of the 17th American Association for Cancer Research-National Cancer Institute-European Organization for Research on Cancer International Conference, November 14-18, 2005. Abstr C230.
33. Smith JA, Wilson L, Azarenko O, et al. Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry. 2010;49:1331-1337.
34. Newman S. Eribulin, a simplified ketone analog of the tubulin inhibitor halichondrin B, for the potential treatment of cancer. Curr Opin Investig Drugs. 2007;8:1057-1066.
35. Zhang ZY, King M, Pelletier RD, Wong YN. Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4. Cancer Chemother Pharmacol. 2008;62:707-716.
36. Synold TW, Morgan RJ, Newman EM, et al. A Phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: A California Cancer Consortium trial. J Clin Oncol. 2005;23 (16 Suppl):3036.
37. Tan AR, Rubin EH, Walton DC, et al. Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res. 2009;15:4213-4219.
38. Goel S, Mita AC, Mita M, et al. A Phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res. 2009; 15:4207-4212.
39. Minami H, Mukohara T, Nagai S, Mukai H, Namiki M. A Phase 1study of eribulin mesylate (E7389) in patients with refractory cancers. Proceeding of 20th American Association for Cancer Research-National Cancer Institute-European Organization for Research on Cancer Symposium on Molecular Targets and Cancer Therapeutics, Geneva, Switzerland, October 21-24, 2008. Abstr 446.
40. Witteveen P, Marchetti S, Mergui-Roelvink M, et al. Eribulin mesylate pharmacokinetics in patients with hepatic impairment. J Clin Oncol. 2010;28:2582.
41. Gupta A, Mould DR, Reyderman L, et al. Population pharmacokineticpharmacodynamic (PK/PD) analysis of safety and efficacy of eribulin in metastatic or locally advanced breast cancer patients. Proceedings of European Society of Medical Oncology annual meeting, Stockholm, Sweden, September 12-16, 2008. Abstr 446.
42. Vahdat LT, Pruitt B, Fabian CJ, et al. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2009;27:2954-2961.
43. Cortes J, Vahdat L, Blum JL, et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2010;28:3922-3928.
44. Iwata H, Aogi K, Masuda N, et al. Efficacy and safety of eribulin in Japanese patients with advanced breast cancer. J Clin Oncol. 2010; 28:1081.
45. Cortes J, O'Shaughnessy J, Loesch D, et al. A Phase III openlabel randomised study (EMBRACE) of eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer. Lancet. 2011;377:914-923.
46. ClinicalTrials.gov. E7389 versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes and refractory to the most recent chemotherapy. Available at: http://clinicaltrials.gov/show/nct00337103. Accessed May 20, 2011.
47. Twelves C, Cortes J, Vahdat LT, Wanders J, Akerele C, Kaufman PA. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clin Breast Cancer. 2010;10:160-163.
48. ClinicalTrials.gov. A study comparing eribulin mesylate and ixabepilone in causing or exacerbating neuropathy in patients with advanced breast cancer. Available at: www.clinicaltrials.gov. Accessed May 20, 2011.
49. ClinicalTrials.gov. A Phase 1b/2, multicenter, randomized, open-label, dose-escalation and confirmation study of eribulin in combination with capecitabine. Available at: www.clinicaltrials.gov. Accessed May 20, 2011.
50. ClinicalTrials.gov. Dose dense doxorubucin and cyclophosphamide followed by eribulin mesylate for the adjuvant treatment of early stage breast cancer. Available at: www.clinicaltrials.gov. Accessed May 20, 2011.
51. ClinicalTrials.gov. A study of single-agent eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor two (HER2) negative breast cancer. Available at: www. clinicaltrials.gov. Accessed May 20, 2011.
52. ClinicalTrials.gov. Eribulin with trastuzumab as first-line therapy for locally recurrent or metastatic HER2 positive breast cancer. Available at: www.clinicaltrials.gov. Accessed May 20, 2011.
53. ClinicalTrials.gov. A study of CDX-011 (CR011-vcMMAE) in patients with advanced GPNMB-expressing breast cancer. Available at: www. clinicaltrials.gov. Accessed May 20, 2011.
54. ClinicalTrials.gov. Compassionate use of eribulin for the treatment of advanced breast cancer refractory to all other marketed therapies. Available at: www.clinicaltrials.gov. Accessed May 20, 2011.
55. ClinicalTrials.gov. An open-label, multi-center, expanded access program with eribulin for the treatment of advanced breast cancer refractory. Available at: www.clinicaltrials.gov. Accessed May 20, 2011.
56. Schoffski P, Ray-Coquard IL, Cioffi A, et al. Activity of eribulin mesylate (E7389) in patients with soft tissue sarcoma (STS): Phase II studies of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC 62052). J Clin Oncol. 2010;28:10031.